Selectivity of dihydropyridines for cardiac L-type and sympathetic N-type Ca2+ channels-Reference-Cited by-同舟云学术

Selectivity of dihydropyridines for cardiac L-type and sympathetic N-type Ca2+ channels

Published:1999-05 Issue:1 Volume:373 Page:93-100
ISSN:0014-2999
Container-title:European Journal of Pharmacology
language:en
Short-container-title:European Journal of Pharmacology

Author:

Uneyama Hisayuki,Uchida Hirohisa,Konda Tomoyuki,Yoshimoto Ryota,Akaike Norio

Publisher

Elsevier BV

Subject

Pharmacology

Reference28 articles.

1. Effect of cilnidipine, a novel dihydropyridine Ca2+-channel antagonist, on N-type Ca2+ channel in rat dorsal root ganglion neurons;Fujii;J. Pharmacol. Exp. Ther.,1997

2. Nifedipine: dose-related increase in mortality in patients with coronary heart disease;Furberg;Circulation,1995

3. Voltage and pH dependent block of cloned N-type Ca2+ channels by amlodipine;Furukawa;Br. J. Pharmacol.,1997

4. Early administration of nifedipine in suspected acute myocardial infarction: the secondary prevention reinfarction Israel nifedipine trial 2 study;Goldbourt;Arch. Intern. Med.,1993

5. Improved patch-clamp technique for high resolution current recording from cells and cell-free membrane patch;Hamill;Pfluegers Arch. Eur. J. Physiol.,1981

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quantitative tracking of trans-synaptic nose-to-brain transport of nanoparticles and its modulation by odor, aging, and Parkinson’s disease;Nano Research;2023-02-16

2. Cilnidipine and magnesium sulfate supplement ameliorates hyperglycemia, dyslipidemia and inhibits oxidative-stress in fructose-induced diabetic rats;Heliyon;2022-01

3. From Calcium Channels to New Therapeutics;Voltage-Gated Calcium Channels;2022

4. An N-/L-type calcium channel blocker, cilnidipine, suppresses autonomic, electrical, and structural remodelling associated with atrial fibrillation;Cardiovascular Research;2019-05-22

5. Investigational calcium channel blockers for the treatment of hypertension;Expert Opinion on Investigational Drugs;2016-10-20